From: Evaluation of CSF albumin quotient in neuronal surface antibody-associated autoimmune encephalitis
Total (n = 93) | Normal Qalb group (n = 60) | Elevated Qalb group (n = 33) | P value | |
---|---|---|---|---|
Female, n (%) | 30 (32.3) | 24 (40.0) | 6 (18.2) | 0.031 |
Onset age, median (IQR) | 42.0 (23.5, 57.5) | 39.5 (23.0, 58.0) | 47.0 (24.0, 56.5) | 0.958 |
Presence of antibody, n (%) | ||||
CSF | 85 (91.4) | 54 (90.0) | 31 (93.9) | 0.793 |
Serum | 23 (24.7) | 17 (28.3) | 6 (18.2) | 0.278 |
Antibody types, n (%) | ||||
NMDAR | 56 (60.2) | 34 (56.7) | 22 (66.7) | 0.491 |
LGI1 | 18 (19.4) | 14 (23.3) | 4 (12.1) | |
GABABR | 13 (14.0) | 9 (15.0) | 4 (12.1) | |
Others | 6 (6.5) | 3 (5.1) | 3 (9.1) | |
Disease duration, days, median (IQR) | 15.0 (7.5, 30.0) | 14.0 (8.0, 30.0) | 15.0 (6.0, 30.0) | 0.885 |
Prodromal symptoms, n (%) | 38 (40.9) | 19 (31.7) | 19 (57.6) | 0.015 |
Concomitant tumors, n (%) | 5 (5.4) | 3 (5.0) | 2 (6.1) | > 0.999 |
Initial symptoms, n (%) | ||||
Seizures | 65 (69.9) | 46 (76.7) | 19 (57.6) | 0.055 |
Psychiatric symptoms | 43 (46.2) | 27 (45.0) | 16 (48.5) | 0.747 |
Memory dysfunction | 31 (33.3) | 21 (35.0) | 10 (30.3) | 0.646 |
Others | 31 (33.3) | 20 (33.3) | 11 (33.3) | > 0.999 |
ICU requirement, n (%) | 8 (8.6) | 4 (6.7) | 4 (12.1) | 0.609 |
The mRS at admission, median (IQR) | 2.0 (1.0, 3.0) | 1.5 (1.0, 2.0) | 2.0 (1.0, 3.0) | 0.145 |